Barely Significant
← all excerpts

Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patients.

ERJ Open Res · 2018 · PMC5810621 · PMID 29450203

1
hedged sentence
closest p
boldest claim

The sentences

a possible trendno p-value reported
Efficacy was similar (ORR 53% versus 51%) regardless of whether ceritinib was administered immediately after crizotinib or not but there was a possible trend for a longer treatment duration in the case of ceritinib being administered immediately (4.2 months versus 3.3 months, respectively).

also in 1,410 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.